Revottack
AXP000134.1 · Oncolytic virus
- Platform
- vesicular stomatitis virus (recombinant)
Names
| Name | Type | Source |
|---|---|---|
| Revottack | preferred name, brand | curator, ctgov |
Virus
- Role
- Oncolytic
- Family
- Rhabdoviridae
- Virus
- vesicular stomatitis Indiana virus (NCBI Taxonomy 11277)
- Replication
- replicating
- Modifications
- not described in the registration
- Route
- intravenous
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05644509 | Study on the Treatment of Advanced Malignant Solid Tumor With Revottack and PD-1 Inhibitor | Unknown | Phase 1 | 2022-12 | 2023-12 | 10 | Advanced Solid Tumor |
Recent changes
No changes recorded in its trials yet.
Notes
Named in NCT05644509 as 'vesicular stomatitis oncolytic virus injection (Revottack)', given intravenously with toripalimab at the Affiliated Hospital of Xuzhou Medical University. Construct, transgenes and developer are not stated anywhere found; NCIt holds only a generic concept C199297 (Oncolytic Vesicular Stomatitis Virus) that also carries an unrelated YSCH-01 synonym, so no ncit code is recorded. Possibly the same product as another Chinese oncolytic VSV (RT-01, VSV-02, OVV-01): unresolved.
How to cite
Revottack (AXP000134.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000134.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.